Health and Healthcare
5864 Articles
Coherus Biosciences Inc. filed an S-1 with the Securities and Exchange Commission for an initial public offering.
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most…
For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams…
Credit Suisse's $36 price target on Sarepta Therapeutics effectively calls for close to 75% upside.
DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering
Exagen Diagnostics Inc. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public…
The Joint Corporation has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public…
Medivation received an upgrade from Canaccord Genuity, citing the company’s potential drug sales of Xtandi as undervalued.
In the after-hours on Wednesday, Flexion Therapeutics made a hard fall on the news of a clinical hold.
Incyte has serious upside potential, but the inherent risk within it may be too much for some investors to bear.
Endo International made an unsolicited buyout offer to Auxilium Pharmaceuticals, right after the latter announced that it had entered into…
Avanir Pharmaceuticals posted amazing gains on Monday following the announcement of a successful Phase 1 trial, but is it now…
Shares of Rewalk Robotics surged again on Monday, following its initial public offering on Friday.
A new research report from UBS focuses on four top companies that are making great strides in treatments for patients…
Avanir Pharmaceuticals announced positive Phase 2 results for its drug candidate AVP-923, a potential new therapy for patients with Alzheimer’s…
Our top personal finance-related articles today. Your wallet will thank you later.